VERTEX ANNOUNCES INITIATION OF DEVELOPMENT PROGRAM FOR AURORA KINASE INHIBITOR

A A

Vertex Pharmaceuticals has begun a Phase II clinical development program for VX-680, an investigational drug candidate targeting Aurora kinase.

The initiation of Phase II development for VX-680 is based on the enrollment of patients with advanced colorectal cancer who may have received up to three prior cancer treatments. The open-label, non-randomized study will enroll approximately 20 patients and is being conducted at major cancer treatment centers in the U.S.